novo nordisk goodrx - Search News

Order byBest matchMost fresh

Novo Nordisk, GoodRx and Ozempic

Novo Nordisk offers Ozempic at $499 per month to eligible US cash-paying customers

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients with type 2 diabetes in the U.S. via its own pharmacy, a tie-up with telehealth service GoodRx and other platforms.

The Pharma Letter · 1d

GoodRx and Novo Nordisk unveil $499 monthly offer for Ozempic and Wegovy

ConsumerAffairs · 15h

GoodRx teams up with Novo Nordisk to make weight loss drugs more affordable

· 9h

Fact Check: Ozempic, other weight-loss drug makers face lawsuits. Here's what we know

Pharmaceutical companies behind weight loss and diabetes medication such as Ozempic are facing a lawsuit that could potentially pay out more than $2 billion.

· 1d

Canada approves Ozempic to cut risk of kidney failure, heart-related deaths

· 1d

Ozempic forced to slash prices after problem emerges

2don MSN

GoodRx stock soars after striking deal to sell Novo Nordisk's GLP-1s for $499/month

GoodRx is joining the GLP-1 action with an announcement Monday to begin selling both of Novo Nordisk's GLP-1 drugs, Ozempic and Wegovy, at a cash price of $499 per month.

2don MSN

Why Novo Nordisk Stock Popped Monday

Shares of Novo Nordisk ( NVO 4.81%), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, jumped 5% through 9:55 a.m. ET Monday on a series of positive announcements for its GLP-1 products.

Stock Movers: Novo Nordisk, GoodRX, CVS

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.

GoodRx: After A 30% Surge On The Novo News, Is The Story Just Beginning?

GoodRx Holdings, Inc.'s partnership with Novo Nordisk highlights its vital role in direct-to-consumer drug pricing. Click here to find out why GDRX is a Buy.

GoodRx (GDRX) Stock Is Sliding Tuesday: What's Going On?

GoodRx shares are pulling back Tuesday morning. The stock had jumped over 30% Monday after the company announced a new partnership with Novo Nordisk.

Novo Nordisk Soars After 50% Ozempic Discount, Liver Treatment Approval

Novo said cash-paying Americans can now buy Ozempic for $499 per month through various channels including its official website.